Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649866 · ClinicalTrials.gov registry record · NA
Coronary Artery Disease in Patients With Friedreich's Ataxia
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT04649866 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 7 participants.
The verdict
NCT04649866, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
Friedreich's ataxia is a debilitating, inherited disease cause by mutations in a protein called frataxin (FXN). FXN is one of several proteins that controls the production of iron-sulfur clusters, molecules that are essential for energy production in our cells as well as repair of our genetic code embedded in DNA molecules. Friedreich's ataxia (FRDA) and deficiency of FXN results in a nerve disease affecting coordination and a condition called hypertrophic cardiomyopathy (HCM), marked by an abnormal thickening of the heart. Patients with HCM can then develop pulmonary hypertension (PH), a deadly condition of the blood vessels of the lung. While most of the research in FRDA has focused on nerves and heart muscle, alterations in blood vessels of the heart and lung may worsen disease in FRDA. But, the role of FXN in these blood vessels has never been defined. Investigators pilot data suggest that Frataxin (FXN ) deficiency can control senescence and downstream function in various types of Endothelial cells (ECs), investigators hypothesize that Friedreich's Ataxia (FRDA) patients may demonstrate endothelial cells EC abnormalities throughout the vasculature potentially before overt cardiomyopathy develops.
Interventions
- DIAGNOSTIC_TEST plethysmography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-02-15 |
| Est. Completion | 2023-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04649866
The ClinicalTrials.gov registry entry for NCT04649866 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which plethysmography is the first listed.
NCT04649866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04649866 about?
NCT04649866 is a clinical study titled "Coronary Artery Disease in Patients With Friedreich's Ataxia". Friedreich's ataxia is a debilitating, inherited disease cause by mutations in a protein called frataxin (FXN). FXN is one of several proteins that controls the production of iron-sulfur clusters, molecules that are essential for energy production in our cells as well as repair of our genetic code e...
What is the current status of trial NCT04649866?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2021-02-15. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT04649866?
The interventions under investigation include: plethysmography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04649866?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.